M2ES + gemcitabine

**M2ES + gemcitabine** is a combination therapy consisting of gemcitabine and an agent designated "M2ES." Gemcitabine is a nucleoside metabolic inhibitor and cytidine analog that, after intracellular phosphorylation, is incorporated into DNA and inhibits DNA synthesis, leading to apoptosis of rapidly dividing tumor cells[6]. Gemcitabine is commonly used for the treatment of solid tumors including ovarian cancer, non-small cell lung cancer, metastatic breast cancer, and pancreatic cancer, both as a monotherapy and in combination with other chemotherapeutics like cisplatin, carboplatin, and paclitaxel[6][3][5]. Information on "M2ES" is not found in available regulatory, clinical, or biomedical sources and is likely a code name or experimental agent not yet characterized in public literature. The combination represents an investigational regimen where **gemcitabine provides antineoplastic activity via DNA synthesis inhibition**, while the mechanism of M2ES is unknown.

Brand names

Gemzar

Other names

M2ESM-2ESM 2ESgemcitabine2',2'-difluorodeoxycytidine